Diabetes, Vol 49, Issue 2 263-271, Copyright © 2000 by American Diabetes Association

ARTICLES

Potential role of glycogen synthase kinase-3 in skeletal muscle insulin resistance of type 2 diabetes

SE Nikoulina, TP Ciaraldi, S Mudaliar, P Mohideen, L Carter and RR Henry
Department of Medicine, University of California, San Diego, La Jolla, USA.

Glycogen synthase (GS) activity is reduced in skeletal muscle of type 2 diabetes, despite normal protein expression, consistent with altered GS regulation. Glycogen synthase kinase-3 (GSK-3) is involved in regulation (phosphorylation and deactivation) of GS. To access the potential role of GSK-3 in insulin resistance and reduced GS activity in type 2 diabetes, the expression and activity of GSK-3 were studied in biopsies of vastus lateralis from type 2 and nondiabetic subjects before and after 3-h hyperinsulinemic (300 mU x m(-2) x min(-1))-euglycemic clamps. The specific activity of GSK-3alpha did not differ between nondiabetic and diabetic muscle and was decreased similarly after 3-h insulin infusion. However, protein levels of both alpha and beta isoforms of GSK-3 were elevated (approximately 30%) in diabetic muscle compared with lean (P < 0.01) and weight-matched obese nondiabetic subjects (P < 0.05) and were unchanged by insulin infusion. Thus, both basal and insulin-stimulated total GSK-3 activities were elevated by approximately twofold in diabetic muscle. GSK-3 expression was related to in vivo insulin action, as GSK-3 protein was negatively correlated with maximal insulin-stimulated glucose disposal rates. In summary, GSK-3 protein levels and total activities are 1) elevated in type 2 diabetic muscle independent of obesity and 2) inversely correlated with both GS activity and maximally insulin-stimulated glucose disposal. We conclude that increased GSK-3 expression in diabetic muscle may contribute to the impaired GS activity and skeletal muscle insulin resistance present in type 2 diabetes.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				P. Poulsen, J. F.P. Wojtaszewski, E. A. Richter, H. Beck-Nielsen, and A. Vaag Low Birth Weight and Zygosity Status Is Associated With Defective Muscle Glycogen and Glycogen Synthase Regulation in Elderly Twins Diabetes, November 1, 2007; 56(11): 2710 - 2714. [Abstract] [Full Text] [PDF]

				T. P. Ciaraldi, S. E. Nikoulina, R. A. Bandukwala, L. Carter, and R. R. Henry Role of Glycogen Synthase Kinase-3{alpha} in Insulin Action in Cultured Human Skeletal Muscle Cells Endocrinology, September 1, 2007; 148(9): 4393 - 4399. [Abstract] [Full Text] [PDF]

				E. R. Gross, A. K. Hsu, and G. J. Gross Diabetes Abolishes Morphine-Induced Cardioprotection via Multiple Pathways Upstream of Glycogen Synthase Kinase-3{beta} Diabetes, January 1, 2007; 56(1): 127 - 136. [Abstract] [Full Text] [PDF]

				T. P. Ciaraldi, D. K. Oh, L. Christiansen, S. E. Nikoulina, A. P. S. Kong, S. Baxi, S. Mudaliar, and R. R. Henry Tissue-specific expression and regulation of GSK-3 in human skeletal muscle and adipose tissue Am J Physiol Endocrinol Metab, November 1, 2006; 291(5): E891 - E898. [Abstract] [Full Text] [PDF]

				B. B. Dokken and E. J. Henriksen Chronic selective glycogen synthase kinase-3 inhibition enhances glucose disposal and muscle insulin action in prediabetic obese Zucker rats Am J Physiol Endocrinol Metab, August 1, 2006; 291(2): E207 - E213. [Abstract] [Full Text] [PDF]

				M.-J. Boucher, L. Selander, L. Carlsson, and H. Edlund Phosphorylation Marks IPF1/PDX1 Protein for Degradation by Glycogen Synthase Kinase 3-dependent Mechanisms J. Biol. Chem., March 10, 2006; 281(10): 6395 - 6403. [Abstract] [Full Text] [PDF]

				O. Kaidanovich-Beilin and H. Eldar-Finkelman Long-Term Treatment with Novel Glycogen Synthase Kinase-3 Inhibitor Improves Glucose Homeostasis in ob/ob Mice: Molecular Characterization in Liver and Muscle J. Pharmacol. Exp. Ther., January 1, 2006; 316(1): 17 - 24. [Abstract] [Full Text] [PDF]

				B. Clodfelder-Miller, P. De Sarno, A. A. Zmijewska, L. Song, and R. S. Jope Physiological and Pathological Changes in Glucose Regulate Brain Akt and Glycogen Synthase Kinase-3 J. Biol. Chem., December 2, 2005; 280(48): 39723 - 39731. [Abstract] [Full Text] [PDF]

				F. Tremblay, M. Krebs, L. Dombrowski, A. Brehm, E. Bernroider, E. Roth, P. Nowotny, W. Waldhausl, A. Marette, and M. Roden Overactivation of S6 Kinase 1 as a Cause of Human Insulin Resistance During Increased Amino Acid Availability Diabetes, September 1, 2005; 54(9): 2674 - 2684. [Abstract] [Full Text] [PDF]

				M. Eto, A. Kouroedov, F. Cosentino, and T. F. Luscher Glycogen Synthase Kinase-3 Mediates Endothelial Cell Activation by Tumor Necrosis Factor-{alpha} Circulation, August 30, 2005; 112(9): 1316 - 1322. [Abstract] [Full Text] [PDF]

				E. A. Medina, R. R. Afsari, T. Ravid, S. S. Castillo, K. L. Erickson, and T. Goldkorn Tumor Necrosis Factor-{alpha} Decreases Akt Protein Levels in 3T3-L1 Adipocytes via the Caspase-Dependent Ubiquitination of Akt Endocrinology, June 1, 2005; 146(6): 2726 - 2735. [Abstract] [Full Text] [PDF]

				B. B. Dokken, J. A. Sloniger, and E. J. Henriksen Acute selective glycogen synthase kinase-3 inhibition enhances insulin signaling in prediabetic insulin-resistant rat skeletal muscle Am J Physiol Endocrinol Metab, June 1, 2005; 288(6): E1188 - E1194. [Abstract] [Full Text] [PDF]

				S. Srinivasan, M. Ohsugi, Z. Liu, S. Fatrai, E. Bernal-Mizrachi, and M. A. Permutt Endoplasmic Reticulum Stress-Induced Apoptosis Is Partly Mediated by Reduced Insulin Signaling Through Phosphatidylinositol 3-Kinase/Akt and Increased Glycogen Synthase Kinase-3{beta} in Mouse Insulinoma Cells Diabetes, April 1, 2005; 54(4): 968 - 975. [Abstract] [Full Text] [PDF]

				K. MacAulay, A. S. Blair, E. Hajduch, T. Terashima, O. Baba, C. Sutherland, and H. S. Hundal Constitutive Activation of GSK3 Down-regulates Glycogen Synthase Abundance and Glycogen Deposition in Rat Skeletal Muscle Cells J. Biol. Chem., March 11, 2005; 280(10): 9509 - 9518. [Abstract] [Full Text] [PDF]

				Z. Liberman and H. Eldar-Finkelman Serine 332 Phosphorylation of Insulin Receptor Substrate-1 by Glycogen Synthase Kinase-3 Attenuates Insulin Signaling J. Biol. Chem., February 11, 2005; 280(6): 4422 - 4428. [Abstract] [Full Text] [PDF]

				F. Yi, P. L. Brubaker, and T. Jin TCF-4 Mediates Cell Type-specific Regulation of Proglucagon Gene Expression by {beta}-Catenin and Glycogen Synthase Kinase-3{beta} J. Biol. Chem., January 14, 2005; 280(2): 1457 - 1464. [Abstract] [Full Text] [PDF]

				K. H. Kim, M. J. Song, E. J. Yoo, S. S. Choe, S. D. Park, and J. B. Kim Regulatory Role of Glycogen Synthase Kinase 3 for Transcriptional Activity of ADD1/SREBP1c J. Biol. Chem., December 10, 2004; 279(50): 51999 - 52006. [Abstract] [Full Text] [PDF]

				C. Bouche, S. Serdy, C. R. Kahn, and A. B. Goldfine The Cellular Fate of Glucose and Its Relevance in Type 2 Diabetes Endocr. Rev., October 1, 2004; 25(5): 807 - 830. [Abstract] [Full Text] [PDF]

				B. Plotkin, O. Kaidanovich, I. Talior, and H. Eldar-Finkelman Insulin Mimetic Action of Synthetic Phosphorylated Peptide Inhibitors of Glycogen Synthase Kinase-3 J. Pharmacol. Exp. Ther., June 1, 2003; 305(3): 974 - 980. [Abstract] [Full Text] [PDF]

				K. Hojlund, P. Staehr, B. F. Hansen, K. A. Green, D. G. Hardie, E. A. Richter, H. Beck-Nielsen, and J. F.P. Wojtaszewski Increased Phosphorylation of Skeletal Muscle Glycogen Synthase at NH2-Terminal Sites During Physiological Hyperinsulinemia in Type 2 Diabetes Diabetes, June 1, 2003; 52(6): 1393 - 1402. [Abstract] [Full Text] [PDF]

				E. J. Henriksen, T. R. Kinnick, M. K. Teachey, M. P. O'Keefe, D. Ring, K. W. Johnson, and S. D. Harrison Modulation of muscle insulin resistance by selective inhibition of GSK-3 in Zucker diabetic fatty rats Am J Physiol Endocrinol Metab, May 1, 2003; 284(5): E892 - E900. [Abstract] [Full Text] [PDF]

				J. T. Brozinick Jr, B. R. Roberts, and G. L. Dohm Defective Signaling Through Akt-2 and -3 But Not Akt-1 in Insulin-Resistant Human Skeletal Muscle: Potential Role in Insulin Resistance Diabetes, April 1, 2003; 52(4): 935 - 941. [Abstract] [Full Text] [PDF]

				D. B. Ring, K. W. Johnson, E. J. Henriksen, J. M. Nuss, D. Goff, T. R. Kinnick, S. T. Ma, J. W. Reeder, I. Samuels, T. Slabiak, et al. Selective Glycogen Synthase Kinase 3 Inhibitors Potentiate Insulin Activation of Glucose Transport and Utilization In Vitro and In Vivo Diabetes, March 1, 2003; 52(3): 588 - 595. [Abstract] [Full Text] [PDF]

				Y.-B. Kim, G. I. Shulman, and B. B. Kahn Fatty Acid Infusion Selectively Impairs Insulin Action on Akt1 and Protein Kinase C lambda /zeta but Not on Glycogen Synthase Kinase-3 J. Biol. Chem., August 30, 2002; 277(36): 32915 - 32922. [Abstract] [Full Text] [PDF]

				S. Maier and A. Olek Diabetes: A Candidate Disease for Efficient DNA Methylation Profiling J. Nutr., August 1, 2002; 132(8): 2440S - 2443. [Abstract] [Full Text] [PDF]

				S. E. Nikoulina, T. P. Ciaraldi, S. Mudaliar, L. Carter, K. Johnson, and R. R. Henry Inhibition of Glycogen Synthase Kinase 3 Improves Insulin Action and Glucose Metabolism in Human Skeletal Muscle Diabetes, July 1, 2002; 51(7): 2190 - 2198. [Abstract] [Full Text] [PDF]

				J. J. Kim, B.-C. Park, Y. Kido, and D. Accili Mitogenic and Metabolic Effects of Type I IGF Receptor Overexpression in Insulin Receptor-Deficient Hepatocytes Endocrinology, August 1, 2001; 142(8): 3354 - 3360. [Abstract] [Full Text] [PDF]

				R. Halse, S. M. Bonavaud, J. L. Armstrong, J. G. McCormack, and S. J. Yeaman Control of Glycogen Synthesis by Glucose, Glycogen, and Insulin in Cultured Human Muscle Cells Diabetes, April 1, 2001; 50(4): 720 - 726. [Abstract] [Full Text]

				S. J. Orena, A. J. Torchia, and R. S. Garofalo Inhibition of Glycogen-synthase Kinase 3 Stimulates Glycogen Synthase and Glucose Transport by Distinct Mechanisms in 3T3-L1 Adipocytes J. Biol. Chem., May 19, 2000; 275(21): 15765 - 15772. [Abstract] [Full Text] [PDF]